A Phase II, Open-Label Trial of Bortezomib (Velcade) in Combination with Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase of Trial: Phase II
Latest Information Update: 01 May 2016
At a glance
- Drugs Bortezomib (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Apr 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Jul 2012 Planned end date changed from 16 Apr 2009 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 03 Jul 2012 New source identified and integrated (NCT01633645: ClinicalTrials.gov: US National Institutes of Health).